Eli Lilly's U.S. stock pre-market surged straight up, currently up over 14%, as the company announced that the weight loss drug Orforglipron achieved its primary endpoint in Phase 3 clinical trials.
Company IR website:
<img src="https://pub.pbkrs.com/uploads/2025/e6f345206f85fc3d3a2959ea25f5f3ff?x-oss-process=style/lg" alt="" original-src="https://pub.pbkrs.com/uploads/2025/e6f345206f85fc3d3a2959ea25f5f3ff"/>

Eli Lilly's U.S. stock surged straight up before the market opened, currently up over 14%, as the company announced that its weight loss drug Orforglipron achieved its primary endpoint in Phase 3 clinical trials

Eli Lilly's U.S. stock pre-market rose over 14% after the company released research data on weight loss medication